Moneycontrol
HomeNewsBusinessMoneycontrol ResearchLupin: Focus on inhalation and bio-similars to aid margins in medium term
Trending Topics
Tata Capital IPO
Advance Agrolife IPO allotment status
Tata Trusts
LG Electronics IPO
Canara Robeco AMC

Lupin: Focus on inhalation and bio-similars to aid margins in medium term

Anubhav Sahu   •

In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets

Themis Medicare | CARE has upgraded long term credit rating on the company's bank facilities to B+/Stable, from B/Stable.

To read the full story,

Subscribe to Moneycontrol PRO
  • Ad-free Experience
  • Access Exclusive Stories
  • Weekly Investment Ideas
  • Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More